Merck KGaA eyes up to 700 million euro Mavenclad sales in EU

FRANKFURT (Reuters) - Germany's Merck KGaA is eyeing annual sales of its multiple sclerosis pill Mavenclad, a late-comer to the market for oral treatments against the neurological disease, of up to 700 million euros ($823 million) in the European Union.